Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + pembrolizumab versus standard of care in previously treated metastatic colorectal cancer
2020-004289-20Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenvatinib, pembrolizumab, regorafenib and trifluridine + tipiracil in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall survival. Started Dec 2020; status: completed.
02
Drugs
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2020-004289-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004289-20.